The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II open label multi-institution study of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) in the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC).
 
Melanie B. Thomas
Honoraria - Celgene
Consulting or Advisory Role - Astellas Pharma; GenSpera
Speakers' Bureau - Celgene; Onyx
Research Funding - Astex Pharmaceuticals; Genentech; Lilly/ImClone; Pfizer
 
Elizabeth Garrett-Mayer
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
Research Funding - Genentech (Inst)
 
Munazza Anis
No Relationships to Disclose
 
Kate Robertson Anderton
No Relationships to Disclose
 
Tricia A Bentz
No Relationships to Disclose
 
Andie Ray Adelman
No Relationships to Disclose
 
Alan Brisendine
No Relationships to Disclose
 
Vinay Duddalwar
Research Funding - GE Healthcare
 
Geoffrey R. Weiss
No Relationships to Disclose
 
Abby B. Siegel
Research Funding - Bayer/Onyx
 
Johanna C. Bendell
No Relationships to Disclose
 
Ari David Baron
Speakers' Bureau - Bristol-Myers Squibb; Genentech
 
Anthony B. El-Khoueiry
Honoraria - Bayer; Onyx; Roche/Genentech
Consulting or Advisory Role - Bayer/Onyx; Onyx; Roche/Genentech
Research Funding - Bayer; Roche/Genentech
Travel, Accommodations, Expenses - Bayer/Onyx; Roche/Genentech